What Dentsply Sirona (XRAY)'s Wider US Distribution Means For Shareholders

• DENTSPLY SIRONA expanded its long-running partnership with Midwest Dental Equipment & Supply, which will distribute the company’s technology portfolio across the US from November 2026. This move broadens access to its digital dentistry solutions through Midwest Dental’s sales, service and technical network.
• The Midwest Dental agreement is the seventh upgraded North American dealer relationship for DENTSPLY SIRONA in 2026. It reflects a continuing effort to widen coverage for its connected technology products and deepen the integration of digital workflows in everyday dental practice operations.
• The next area of attention is how DENTSPLY SIRONA’s investment narrative could evolve as expanded Midwest Dental distribution supports its digital dentistry strategy.

Scan how DENTSPLY SIRONA’s distribution-led push compares with other health-focused plays by reviewing the hand-picked list of solid balance sheet and fundamentals (25 results) for potential ideas to research alongside XRAY.

DENTSPLY SIRONA Investment Narrative Recap

DENTSPLY SIRONA appeals to shareholders who believe its digital dentistry platforms, consumables and Wellspect healthcare assets can eventually support steadier earnings after a long stretch of weak returns. In the near term, the key issue is execution on sales coverage and cost programs while demand in higher margin elective categories such as implants, CAD/CAM and imaging remains soft.

The fresh debt covenant amendments look more like housekeeping than a clear catalyst. They are intended to keep the balance sheet compliant as EBIT pressure and tariffs bite, but tighter limits on new liens, subsidiary borrowing and restricted payments also underline that leverage and execution missteps remain the central risk for now.

The Third Amendment to the credit facility and the series of Note Purchase Agreement amendments matter most today because they frame how DENTSPLY SIRONA can fund its commercial push. Higher permitted leverage ratios and temporary EBITDA addbacks give the group room to absorb restructuring costs and soft elective demand without tripping covenants.

There is a tradeoff. Added pricing tiers on the revolver and higher incremental interest if leverage moves above set thresholds mean financing could become more expensive just as tariffs, competition and prior impairments weigh on returns. For investors, progress on digital adoption and cost savings now has to be assessed alongside tighter debt guardrails.

DENTSPLY SIRONA's analyst narrative points to revenues of US$3.8b and earnings of US$189.7m by 2029, based on relatively flat annual revenue trends and an earnings change of about US$817.7m from a current loss of US$628.0m.

Uncover how DENTSPLY SIRONA's fair value indicates a 56% potential upside to its current price that could narrow quickly if sentiment turns.

Exploring Other Perspectives

One alternate take on DENTSPLY SIRONA leans heavily on digital acceleration. The most optimistic analysts were already forecasting about US$3.9b of revenue and US$373.4m of earnings by 2029 before this Midwest Dental deal and the covenant changes. You can treat those as an upper-bound scenario and compare them with more cautious views.

Explore 2 other DENTSPLY SIRONA fair value estimates, including one that suggests potential upside of up to 431% from the current price!

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for DENTSPLY SIRONA. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Looking For More DENTSPLY SIRONA Sized Investment Ideas?

If you want to put DENTSPLY SIRONA in context and build a broader watchlist, use the Simply Wall St Screener to line it up alongside other businesses with similar qualities.

• For investors who care most about resilient balance sheets and steady fundamentals, scan a curated list of solid balance sheet and fundamentals (25 results) that can sit next to XRAY on your research list.
• If you are hunting for mispriced opportunities, compare DENTSPLY SIRONA with a hand picked set of 33 high quality undervalued stocks that may warrant a spot on your radar.
• Income focused readers can round out their view by weighing XRAY against 8 dividend fortresses that combine elevated yields with a focus on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com